Combining radiotherapy with immunoscheckpoint inhibitors or CAR-T in renal cell carcinoma

Matteo Santoni; Daniel Y.C. Heng; Gaetano Aurilio; Andrea Iozzelli; Lucilla Servi; Andrea Fabiani; Massimo Giannini; Roberta Mazzucchelli; Alessia Cimadamore; Marina Scarpelli; Mohamed S. Zaghloul; Nicola Battelli; Rodolfo Montironi

doi:10.2174/1389450120666191017113051

Combining radiotherapy with immunoscheckpoint inhibitors or CAR-T in renal cell carcinoma

Matteo Santoni, Daniel Y.C. Heng, Gaetano Aurilio, Andrea Iozzelli, Lucilla Servi, Andrea Fabiani, Massimo Giannini, Roberta Mazzucchelli, Alessia Cimadamore, Marina Scarpelli, Mohamed S. Zaghloul, Nicola Battelli, Rodolfo Montironi

Research output: Contribution to journal › Article › peer-review

Abstract

Radiotherapy is considered a second life in Renal Cell Carcinoma (RCC) patients, mainly due to the introduction of immune checkpoint inhibitors, such as anti-Programmed-death (PD)-1, alone or in combination with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4. Several trials are investigating the efficacy/safety of immune checkpoint inhibitors in sequential or combined strategies with radiotherapy. Chimeric Antigen Receptor (CAR)-T cells therapy as a promising approach in cancer patients has opened the way to novel possibilities of integrating therapies. The identification of biomarkers of tumor response to these combinations represents a challenge in RCC, together with the research for the best partner for immunotherapy in metastatic patients. In this review we illustrated preclinical/clinical data on the integration of radiotherapy with immunocheckpoint inhibitors or CART cells in RCC.

Original language	English
Pages (from-to)	416-423
Number of pages	8
Journal	Current Drug Targets
Volume	21
Issue number	4
DOIs	https://doi.org/10.2174/1389450120666191017113051
Publication status	Published - 2020

Keywords

CAR-T cells
Immunocheckpoint inhibitors
Immunotherapy
Programmed-death-1
Radiation therapy
Renal cell carcinoma

ASJC Scopus subject areas

Molecular Medicine
Pharmacology
Drug Discovery
Clinical Biochemistry

Access to Document

10.2174/1389450120666191017113051

Cite this

Santoni, M., Heng, D. Y. C., Aurilio, G., Iozzelli, A., Servi, L., Fabiani, A., Giannini, M., Mazzucchelli, R., Cimadamore, A., Scarpelli, M., Zaghloul, M. S., Battelli, N., & Montironi, R. (2020). Combining radiotherapy with immunoscheckpoint inhibitors or CAR-T in renal cell carcinoma. Current Drug Targets, 21(4), 416-423. https://doi.org/10.2174/1389450120666191017113051

Combining radiotherapy with immunoscheckpoint inhibitors or CAR-T in renal cell carcinoma. / Santoni, Matteo; Heng, Daniel Y.C.; Aurilio, Gaetano; Iozzelli, Andrea; Servi, Lucilla; Fabiani, Andrea; Giannini, Massimo; Mazzucchelli, Roberta; Cimadamore, Alessia; Scarpelli, Marina; Zaghloul, Mohamed S.; Battelli, Nicola; Montironi, Rodolfo.

In: Current Drug Targets, Vol. 21, No. 4, 2020, p. 416-423.

Research output: Contribution to journal › Article › peer-review

Santoni, Matteo ; Heng, Daniel Y.C. ; Aurilio, Gaetano ; Iozzelli, Andrea ; Servi, Lucilla ; Fabiani, Andrea ; Giannini, Massimo ; Mazzucchelli, Roberta ; Cimadamore, Alessia ; Scarpelli, Marina ; Zaghloul, Mohamed S. ; Battelli, Nicola ; Montironi, Rodolfo. / Combining radiotherapy with immunoscheckpoint inhibitors or CAR-T in renal cell carcinoma. In: Current Drug Targets. 2020 ; Vol. 21, No. 4. pp. 416-423.

@article{12328ac69d1143ef8319b87e261ec918,

title = "Combining radiotherapy with immunoscheckpoint inhibitors or CAR-T in renal cell carcinoma",

abstract = "Radiotherapy is considered a second life in Renal Cell Carcinoma (RCC) patients, mainly due to the introduction of immune checkpoint inhibitors, such as anti-Programmed-death (PD)-1, alone or in combination with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4. Several trials are investigating the efficacy/safety of immune checkpoint inhibitors in sequential or combined strategies with radiotherapy. Chimeric Antigen Receptor (CAR)-T cells therapy as a promising approach in cancer patients has opened the way to novel possibilities of integrating therapies. The identification of biomarkers of tumor response to these combinations represents a challenge in RCC, together with the research for the best partner for immunotherapy in metastatic patients. In this review we illustrated preclinical/clinical data on the integration of radiotherapy with immunocheckpoint inhibitors or CART cells in RCC.",

keywords = "CAR-T cells, Immunocheckpoint inhibitors, Immunotherapy, Programmed-death-1, Radiation therapy, Renal cell carcinoma",

author = "Matteo Santoni and Heng, {Daniel Y.C.} and Gaetano Aurilio and Andrea Iozzelli and Lucilla Servi and Andrea Fabiani and Massimo Giannini and Roberta Mazzucchelli and Alessia Cimadamore and Marina Scarpelli and Zaghloul, {Mohamed S.} and Nicola Battelli and Rodolfo Montironi",

year = "2020",

doi = "10.2174/1389450120666191017113051",

language = "English",

volume = "21",

pages = "416--423",

journal = "Current Drug Targets",

issn = "1389-4501",

publisher = "Bentham Science Publishers B.V.",

number = "4",

}

TY - JOUR

T1 - Combining radiotherapy with immunoscheckpoint inhibitors or CAR-T in renal cell carcinoma

AU - Santoni, Matteo

AU - Heng, Daniel Y.C.

AU - Aurilio, Gaetano

AU - Iozzelli, Andrea

AU - Servi, Lucilla

AU - Fabiani, Andrea

AU - Giannini, Massimo

AU - Mazzucchelli, Roberta

AU - Cimadamore, Alessia

AU - Scarpelli, Marina

AU - Zaghloul, Mohamed S.

AU - Battelli, Nicola

AU - Montironi, Rodolfo

PY - 2020

Y1 - 2020

N2 - Radiotherapy is considered a second life in Renal Cell Carcinoma (RCC) patients, mainly due to the introduction of immune checkpoint inhibitors, such as anti-Programmed-death (PD)-1, alone or in combination with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4. Several trials are investigating the efficacy/safety of immune checkpoint inhibitors in sequential or combined strategies with radiotherapy. Chimeric Antigen Receptor (CAR)-T cells therapy as a promising approach in cancer patients has opened the way to novel possibilities of integrating therapies. The identification of biomarkers of tumor response to these combinations represents a challenge in RCC, together with the research for the best partner for immunotherapy in metastatic patients. In this review we illustrated preclinical/clinical data on the integration of radiotherapy with immunocheckpoint inhibitors or CART cells in RCC.

AB - Radiotherapy is considered a second life in Renal Cell Carcinoma (RCC) patients, mainly due to the introduction of immune checkpoint inhibitors, such as anti-Programmed-death (PD)-1, alone or in combination with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4. Several trials are investigating the efficacy/safety of immune checkpoint inhibitors in sequential or combined strategies with radiotherapy. Chimeric Antigen Receptor (CAR)-T cells therapy as a promising approach in cancer patients has opened the way to novel possibilities of integrating therapies. The identification of biomarkers of tumor response to these combinations represents a challenge in RCC, together with the research for the best partner for immunotherapy in metastatic patients. In this review we illustrated preclinical/clinical data on the integration of radiotherapy with immunocheckpoint inhibitors or CART cells in RCC.

KW - CAR-T cells

KW - Immunocheckpoint inhibitors

KW - Immunotherapy

KW - Programmed-death-1

KW - Radiation therapy

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85081259085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081259085&partnerID=8YFLogxK

U2 - 10.2174/1389450120666191017113051

DO - 10.2174/1389450120666191017113051

M3 - Article

C2 - 31625471

AN - SCOPUS:85081259085

VL - 21

SP - 416

EP - 423

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 4

ER -

Combining radiotherapy with immunoscheckpoint inhibitors or CAR-T in renal cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this